Amedisys' Q2 adjusted EPS beats estimates

Amedisys

29/07/2025 21:57

Overview

Amedisys Q2 net service revenue rises to $621.9 mln from $591.2 mln

Adjusted EPS for Q2 beats estimates, reaching $1.54, per LSEG data

Adjusted EBITDA of $80.8 mln surpasses analyst expectations, per LSEG data

Result Drivers

MERGER EXPENSES - Higher merger-related expenses impacted net income, reducing it to $28.1 mln from $32.3 mln in Q2 2024

REVENUE INCREASE - Net service revenue rose by $30.7 mln to $621.9 mln, driven by growth in healthcare services

ADJUSTED EBITDA GROWTH - Adjusted EBITDA increased to $80.8 mln, surpassing analyst expectations, attributed to operational efficiencies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$1.54
$1.33 (10 Analysts)
Q2 Adjusted Net Income
Beat
$51.40 mln
$45.20 mln (7 Analysts)
Q2 Net Income
$28.10 mln
Q2 Adjusted EBITDA
Beat
$80.80 mln
$71.50 mln (11 Analysts)
Q2 Net Service Revenue
$621.90 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 10 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Amedisys Inc is $101.00, about 4% above its July 28 closing price of $96.91

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nGNX89vGwd

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)